Partner David Rosen provides an overview of the Food and Drug Administration’s increasing use of consent decrees as compliance enforcement tools, stating that companies can potentially improve their manufacturing operations and systems quality by efficiently meeting the terms and conditions of a consent decree. He adds that entering into a consent decree requires significant time and resources, but notes that companies can better meet these requirements by proactively investing in a comprehensive quality program.
Click here to read the complete article.
Author(s)
Related Insights
July 25, 2025
Foley Viewpoints
Thorny Laws That ICHRA Vendors Should Consider, Part Three: FinTech Edition
We continue our series on the legal and regulatory challenges facing individual coverage health reimbursement arrangements (ICHRAs); this…
July 24, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
July 23, 2025
Foley Viewpoints
The One Big Beautiful Bill and Workplace Immigration Enforcement
The “One Big Beautiful Bill Act,” signed into law by President Trump on July 4, 2025, will fund government efforts to continue to…